Please use this identifier to cite or link to this item: https://repository.iimb.ac.in/handle/2074/21287
DC FieldValueLanguage
dc.contributor.advisorDamodaran, Appukuttan
dc.contributor.authorAgarwal, Rishabh
dc.date.accessioned2022-06-28T09:26:47Z-
dc.date.available2022-06-28T09:26:47Z-
dc.date.issued2021
dc.identifier.urihttps://repository.iimb.ac.in/handle/2074/21287-
dc.description.abstractCOVAX is a global body comprising of WHO, GAVI, CEPI and UNICEF that was tasked with providing 2 billion vaccines worldwide by 2021. Most of these vaccines were to be provided to low- and middle-income countries. However, they could only deliver 240 million. Reasons for this failure were a lack of proper funding, high bargaining power of vaccine manufacturers, vaccine nationalism adopted by rich countries and trade restrictions. Going forward, COVAX needs to secure more trustworthy and alternate sources of finance as well as increased commitment from vaccine manufacturers. Further, trade and IP laws should be relaxed for the purpose of vaccine manufacturing and delivery.
dc.publisherIndian Institute of Management Bangalore
dc.relation.ispartofseriesPGP_CCS_P21_055
dc.subjectCOVAX
dc.subjectCovid-19
dc.subjectDiseases
dc.subjectVaccination
dc.subjectHealthcare
dc.subjectMedicine
dc.titleCOVAX facility and its effectiveness in distributing covid-19 vaccines
dc.typeCCS Project Report-PGP
dc.pages10p.
Appears in Collections:2021
Files in This Item:
File SizeFormat 
PGP_CCS_P21_055.pdf1.03 MBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.